CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Havre, Pamela A ^a   Dang, Long H ^a   Ohnuma, Kei ^b   Iwata, Satoshi ^b   Morimoto, Chikao ^b   Dang, Nam H ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b JUNTENDO UNIVERSITY   (Japan)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adhesion; CD26; Cell signaling; MT1 MMP; T cell malignancies

Indexed keywords

COLLAGEN TYPE 1; COLLAGENASE; DIPEPTIDYL PEPTIDASE IV; HERMES ANTIGEN; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VERSICAN;

ARTICLE; BIOTINYLATION; CARCINOGENESIS; CELL ADHESION; CELL ASSAY; CELL CLONE; CELL INVASION; CELL VACUOLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; T LYMPHOCYTE; VIRUS PARTICLE; WESTERN BLOTTING;

ANTIGENS, CD44; CELL ADHESION; CELL LINE, TUMOR; COLLAGEN TYPE I; COLLAGENASES; DIPEPTIDYL PEPTIDASE 4; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MATRIX METALLOPROTEINASE 14; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; VERSICANS;

EID: 84886740175     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-517     Document Type: Article

References (67)

1. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6(6):603-615. 10.1016/j.stem.2010.04.001, 20569697.
2. de Andrade CF, Bigni R, Pombo-de-Oliveira MS, Alves G, Pereira DA. CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. J Enzyme Inhib Med Chem 2009, 24(3):708-714. 10.1080/14756360802334800, 19469710.
3. De Chiara L, Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, Cordero OJ, Martinez-Ares D, Paez de la Cadena M. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer 2010, 10:333. 10.1186/1471-2407-10-333, 2912863, 20584285.
4. Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoi E, Kokubun S. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology 2009, 55(4):432-440. 10.1111/j.1365-2559.2009.03399.x, 2784039, 19817894.
5. Varona A, Blanco L, Perez I, Gil J, Irazusta J, Lopez JI, Candenas ML, Pinto FM, Larrinaga G. Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer 2010, 10:193. 10.1186/1471-2407-10-193, 2876082, 20459800.
6. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 2005, 65(4):1325-1334. 10.1158/0008-5472.CAN-04-1852, 15735018.
7. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S. Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res 2002, 62(10):2753-2757.
8. Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee KS, Morimoto C, Dang NH. CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res 2005, 65(15):6950-6956. 10.1158/0008-5472.CAN-05-0647, 16061680.
9. Ohnuma K, Yamochi T, Uchiyama M, Nishibashi K, Yoshikawa N, Shimizu N, Iwata S, Tanaka H, Dang NH, Morimoto C. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci USA 2004, 101(39):14186-14191. 10.1073/pnas.0405266101, 521134, 15353589.
10. Fox DA, Hussey RE, Fitzgerald KA, Acuto O, Poole C, Palley L, Daley JF, Schlossman SF, Reinherz EL. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984, 133(3):1250-1256.
11. Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C. Comitogenic effect of solid-phase immobilized anti-1 F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 1990, 144(11):4092-4100.
12. Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, Schlossman SF, Morimoto C. Cell surface modulation of CD26 by anti-1 F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol 1990, 145(12):3963-3971.
13. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 1991, 147(8):2514-2517.
14. Carbone A, Gloghini A, Zagonel V, Aldinucci D, Gattei V, Degan M, Improta S, Sorio R, Monfardini S, Pinto A. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 1995, 86(12):4617-4626.
15. Dang NH, Aytac U, Sato K, O'Brien S, Melenhorst J, Morimoto C, Barrett AJ, Molldrem JJ. T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol 2003, 121(6):857-865. 10.1046/j.1365-2141.2003.04365.x, 12786796.
16. Yamaguchi U, Nakayama R, Honda K, Ichikawa H, Hasegawa T, Shitashige M, Ono M, Shoji A, Sakuma T, Kuwabara H, et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 2008, 26(25):4100-4108. 10.1200/JCO.2007.14.2331, 18757323.
17. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 2007, 13(14):4191-4200. 10.1158/1078-0432.CCR-07-0110, 17634548.
18. Droz D, Zachar D, Charbit L, Gogusev J, Chretein Y, Iris L. Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol 1990, 137(4):895-905. 1877557, 1699423.
19. Le Naour F, Andre M, Greco C, Billard M, Sordat B, Emile J-F, Lanza F, Boucheix C, Rubinstein E. Profiling of the Tetraspanin web of human colon cancer cells. Mol Cell Proteomics 2006, 5(5):845-857. 10.1074/mcp.M500330-MCP200, 16467180.
20. Stange T, Kettmann U, Holzhausen HJ. Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells. Eur J Histochem 2000, 44(2):157-164.
21. Javidroozi M, Zucker S, Chen WT. Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis Markers 2012, 32(5):309-320. 10.1155/2012/706745, 22674411.
22. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion. Br J Cancer 2009, 101(6):983-991. 10.1038/sj.bjc.6605236, 2743358, 19654580.
23. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002, 14(5):617-623. 10.1016/S0955-0674(02)00375-7, 12231358.
24. Yamagata M, Yamada KM, Yoneda M, Suzuki S, Kimata K. Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem 1986, 261(29):13526-13535.
25. Theocharis AD. Versican in health and disease. Connect Tissue Res 2008, 49(3):230-234.
26. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005, 15(7):483-494. 10.1038/sj.cr.7290318, 16045811.
27. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009, 28(1-2):233-245.
28. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 2010, 277(19):3904-3923. 10.1111/j.1742-4658.2010.07800.x, 20840587.
29. Cattaruzza S, Schiappacassi M, Ljungberg-Rose A, Spessotto P, Perissinotto D, Morgelin M, Mucignat MT, Colombatti A, Perris R. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem 2002, 277(49):47626-47635. 10.1074/jbc.M206521200, 12221092.
30. Dolo V, Adobati E, Canevari S, Picone MA, Vittorelli ML. Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis 1995, 13(4):277-286. 10.1007/BF00133483, 7606890.
31. Wolf K, Muller R, Borgmann S, Brocker EB, Friedl P. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood 2003, 102(9):3262-3269. 10.1182/blood-2002-12-3791, 12855577.
32. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, Lopez-Otin C, Shapiro S, Inada M, Krane S, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004, 167(4):769-781. 10.1083/jcb.200408028, 2172570, 15557125.
33. Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M, Sato H. Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res 2004, 64(3):1044-1049. 10.1158/0008-5472.CAN-03-1843, 14871836.
34. Gingras D, Beliveau R. Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity. Biochim Biophys Acta 2010, 1803(1):142-150. 10.1016/j.bbamcr.2009.04.011, 19409422.
35. Mori H, Tomari T, Koshikawa N, Kajita M, Itoh Y, Sato H, Tojo H, Yana I, Seiki M. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 2002, 21(15):3949-3959. 10.1093/emboj/cdf411, 126155, 12145196.
36. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001, 153(5):893-904. 10.1083/jcb.153.5.893, 2174329, 11381077.
37. Ladeda V, Aguirre Ghiso JA, Bal de Kier Joffe E. Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells. Exp Cell Res 1998, 242(2):515-527. 10.1006/excr.1998.4094, 9683538.
38. Williams KC, Coppolino MG. Phosphorylation of membrane type 1-matrix metalloproteinase (MT1-MMP) and its vesicle-associated membrane protein 7 (VAMP7)-dependent trafficking facilitate cell invasion and migration. J Biol Chem 2011, 286(50):43405-43416. 10.1074/jbc.M111.297069, 3234865, 22002060.
39. Zucker S, Hymowitz M, Conner CE, DiYanni EA, Cao J. Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase a activation. Lab Invest 2002, 82(12):1673-1684. 10.1097/01.LAB.0000041713.74852.2A, 12480917.
40. Kean MJ, Williams KC, Skalski M, Myers D, Burtnik A, Foster D, Coppolino MG. VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. J Cell Sci 2009, 122(Pt 22):4089-4098.
41. Evans RD, Itoh Y. Analyses of MT1-MMP activity in cells. Methods Mol Med 2007, 135:239-249. 10.1007/978-1-59745-401-8_15, 17951663.
42. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res 2012, 72(1):365-374. 10.1158/0008-5472.CAN-11-1831, 3286642, 22086849.
43. Tanimura S, Asato K, Fujishiro SH, Kohno M. Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun 2003, 304(4):801-806. 10.1016/S0006-291X(03)00670-3, 12727228.
44. Gingras D, Bousquet-Gagnon N, Langlois S, Lachambre MP, Annabi B, Beliveau R. Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). FEBS Lett 2001, 507(2):231-236. 10.1016/S0014-5793(01)02985-4, 11684104.
45. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002, 160(2):673-680. 10.1016/S0002-9440(10)64887-0, 1850663, 11839588.
46. Hakulinen J, Sankkila L, Sugiyama N, Lehti K, Keski-Oja J. Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J Cell Biochem 2008, 105(5):1211-1218. 10.1002/jcb.21923, 18802920.
47. Chun TH, Sabeh F, Ota I, Murphy H, McDonagh KT, Holmbeck K, Birkedal-Hansen H, Allen ED, Weiss SJ. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 2004, 167(4):757-767. 10.1083/jcb.200405001, 2172577, 15545316.
48. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002, 16(6):555-564. 10.1096/fj.01-0790com, 11919158.
49. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011, 278(1):16-27. 10.1111/j.1742-4658.2010.07919.x, 21087457.
50. Dang NH, Torimoto Y, Schlossman SF, Morimoto C. Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1 F7 and VLA integrin family. J Exp Med 1990, 172(2):649-652. 10.1084/jem.172.2.649, 2188344, 2165129.
51. Loster K, Zeilinger K, Schuppan D, Reutter W. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun 1995, 217(1):341-348. 10.1006/bbrc.1995.2782, 8526932.
52. Cheng HC, Abdel-Ghany M, Pauli BU. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem 2003, 278(27):24600-24607. 10.1074/jbc.M303424200, 12716896.
53. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 2006, 66(6):3034-3043. 10.1158/0008-5472.CAN-05-2177, 16540652.
54. Clark ES, Weaver AM. A new role for cortactin in invadopodia: regulation of protease secretion. Eur J Cell Biol 2008, 87(8-9):581-590. 2566933, 18342393.
55. Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA 1997, 94(15):7959-7964. 10.1073/pnas.94.15.7959, 21537, 9223295.
56. Wang Y, McNiven MA. Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol 2012, 196(3):375-385. 10.1083/jcb.201105153, 3275373, 22291036.
57. Tague SE, Muralidharan V, D'Souza-Schorey C. ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci USA 2004, 101(26):9671-9676. 10.1073/pnas.0403531101, 470733, 15210957.
58. Takino T, Tsuge H, Ozawa T, Sato H. MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix. Biochem Biophys Res Commun 2010, 396(4):1042-1047. 10.1016/j.bbrc.2010.05.059, 20471961.
59. Howe AK, Aplin AE, Juliano RL. Anchorage-dependent ERK signaling-mechanisms and consequences. Curr Opin Genet Dev 2002, 12(1):30-35. 10.1016/S0959-437X(01)00260-X, 11790551.
60. Gonzalo P, Moreno V, Galvez BG, Arroyo AG. MT1-MMP and integrins: hand-to-hand in cell communication. Biofactors 2010, 36(4):248-254. 10.1002/biof.99, 20818710.
61. Ramsay AG, Marshall JF, Hart IR. Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev 2007, 26(3-4):567-578.
62. Rahmani M, Read JT, Carthy JM, McDonald PC, Wong BW, Esfandiarei M, Si X, Luo Z, Luo H, Rennie PS, et al. Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem 2005, 280(13):13019-13028.
63. Ghersi G, Zhao Q, Salamone M, Yeh Y, Zucker S, Chen WT. The protease complex consisting of dipeptidyl peptidase IV and Seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res 2006, 66(9):4652-4661. 10.1158/0008-5472.CAN-05-1245, 1457118, 16651416.
64. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994, 91(12):5657-5661. 10.1073/pnas.91.12.5657, 44055, 7911242.
65. Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen WT. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 2002, 277(32):29231-29241. 10.1074/jbc.M202770200, 12023964.
66. Sedo A, Stremenova J, Busek P, Duke-Cohan JS. Dipeptidyl peptidase-IV and related molecules: markers of malignancy?. Exp Opin Med Diagn 2008, 2(6):677-689.
67. Suenaga N, Mori H, Itoh Y, Seiki M. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene 2005, 24(5):859-868. 10.1038/sj.onc.1208258, 15558018.